<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Availability</title>
	<atom:link href="http://www.tapanray.in/tag/availability/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Meeting India’s Unmet Biologic Drug Needs Some Global Synergy Evident &#8211; But Patients Need More</title>
		<link>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more</link>
		<comments>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/#comments</comments>
		<pubDate>Mon, 17 Jul 2023 00:00:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[Biosimilar. drugs]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unmet]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10799</guid>
		<description><![CDATA[Many reports have vindicated the rapidly growing importance of biologic drugs in the treatment of a wide range of complex ailments. These include autoimmune diseases, cancers, hormonal irregularities, anemia, and to prevent various diseases such as vaccines, have drawn healthcare &#8230; <a href="http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Exploring An Exit To India’s Covid Management Maze</title>
		<link>http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=exploring-an-exit-to-indias-covid-management-maze</link>
		<comments>http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/#comments</comments>
		<pubDate>Mon, 03 May 2021 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covaxin]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[Covid 2.0]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Covishield]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[exit]]></category>
		<category><![CDATA[Exploring]]></category>
		<category><![CDATA[imported]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian Patent Act]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[maze]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 100]]></category>
		<category><![CDATA[Section 92]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Sputnik V]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10487</guid>
		<description><![CDATA[‘India’s Covid-19 Crisis is Spiraling Out of Control. It Didn’t Have to Be This Way,’ was the headline of the lead article, published in The Time with the cover page ‘India in Crisis.’ All Indians also believe the same, as the current &#8230; <a href="http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India Being World’s Third largest Covid Vaccine Maker: Will All Indians Benefit?</title>
		<link>http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit</link>
		<comments>http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/#comments</comments>
		<pubDate>Mon, 02 Nov 2020 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[all third]]></category>
		<category><![CDATA[ambiguity]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[Bihar]]></category>
		<category><![CDATA[cold-chain]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[countrywide]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[election]]></category>
		<category><![CDATA[equitable]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indians]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[largest]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[maker]]></category>
		<category><![CDATA[manufacturer]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[Nationalism]]></category>
		<category><![CDATA[oxfam]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Serum Institute of India]]></category>
		<category><![CDATA[SII]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uninterrupted]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[virus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10311</guid>
		<description><![CDATA[Apprehensions on the time of availability notwithstanding, equitable access to Covid vaccines for all, remain the best hope to leash the deadly virus, as the pandemic overwhelms the world. According to the World Health Organization (WHO) ‘Coronavirus Update 37’ of October 06, &#8230; <a href="http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Digital Tools To Protect From Infection, Neutralize Covid-19</title>
		<link>http://www.tapanray.in/new-digital-tools-to-protect-from-infection-neutralize-covid-19/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-digital-tools-to-protect-from-infection-neutralize-covid-19</link>
		<comments>http://www.tapanray.in/new-digital-tools-to-protect-from-infection-neutralize-covid-19/#comments</comments>
		<pubDate>Mon, 03 Aug 2020 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Devices]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[initiatives]]></category>
		<category><![CDATA[neutralize]]></category>
		<category><![CDATA[overworked]]></category>
		<category><![CDATA[prevent]]></category>
		<category><![CDATA[protect]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Shycocan]]></category>
		<category><![CDATA[spread]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tech]]></category>
		<category><![CDATA[technological]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[transmission]]></category>
		<category><![CDATA[workers]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10209</guid>
		<description><![CDATA[There seems to be some light at the end of the dark tunnel of a serious biological threat that the world is passing through, since the nightmarish last seven months. The COVID-19 pandemic has spread to 213 countries and territories, and the number &#8230; <a href="http://www.tapanray.in/new-digital-tools-to-protect-from-infection-neutralize-covid-19/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-digital-tools-to-protect-from-infection-neutralize-covid-19/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid-19 Drugs: Accessibility, Affordability And Availability</title>
		<link>http://www.tapanray.in/covid-19-drugs-accessibility-affordability-and-availability/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-19-drugs-accessibility-affordability-and-availability</link>
		<comments>http://www.tapanray.in/covid-19-drugs-accessibility-affordability-and-availability/#comments</comments>
		<pubDate>Mon, 27 Jul 2020 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[accessibility]]></category>
		<category><![CDATA[affordable affordability]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[available]]></category>
		<category><![CDATA[catastrophe]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manufacturers]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[skepticism]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10198</guid>
		<description><![CDATA[Covid-19 continues refusing to unravel the key to neutralize its destructive power &#8211; for bringing human life and the socioeconomic fabric of a country back to the old normal again. Just as India, all other countries are, apparently, awaiting a &#8230; <a href="http://www.tapanray.in/covid-19-drugs-accessibility-affordability-and-availability/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-19-drugs-accessibility-affordability-and-availability/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Supreme Court Intervened…But ‘Price Control’ needs striking a right balance between ‘Affordability’ and ‘Availability’ of medicines for Patients’ Sake</title>
		<link>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients</link>
		<comments>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/#comments</comments>
		<pubDate>Mon, 08 Oct 2012 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[balance]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intervened]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[medicines for Patients’ Sake]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1084</guid>
		<description><![CDATA[On October 3, 2012, the Supreme Court bench of Justice GS Singhvi and Justice SJ Mukhopadhayareportedly asked the government not to disturb the existing price control mechanism while including all medicines featuring  in the National List of Essential Medicines 2011 (NLEM &#8230; <a href="http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
